...and what a year it had been. In terms of research we've seen two candidate drugs move up the development scale.
Isis Pharmaceuticals' antisense drug designed to treat Spinal Muscular Atrophy (SMA), Isis SMNrx entered phase 1 clinical study. The study is estimated to be completed by October 2012.
A bit further along in the development is Trophos' drug Olesoxime. In October 2011 it entered a phase 2 clinical study that recruited over 160 patients with SMA. Efficacy results are expected in the second half of 2013.
In November the Swiss pharmaceutical giant Roche signed a licensing agreement for PTC Therapeutics' SMA programme. This makes Roche the second pharmaceutical giant that is trying to find a cure for SMA. Novartis has been running a high throughput screening campaign for some time now.
Other tentative new drugs are being researched and scientists are gaining an ever deeper understanding of the disease.
Looking forward to all the great news that 2012 is going to bring us.
Happy New Year!
Isis Pharmaceuticals' antisense drug designed to treat Spinal Muscular Atrophy (SMA), Isis SMNrx entered phase 1 clinical study. The study is estimated to be completed by October 2012.
A bit further along in the development is Trophos' drug Olesoxime. In October 2011 it entered a phase 2 clinical study that recruited over 160 patients with SMA. Efficacy results are expected in the second half of 2013.
In November the Swiss pharmaceutical giant Roche signed a licensing agreement for PTC Therapeutics' SMA programme. This makes Roche the second pharmaceutical giant that is trying to find a cure for SMA. Novartis has been running a high throughput screening campaign for some time now.
Other tentative new drugs are being researched and scientists are gaining an ever deeper understanding of the disease.
Looking forward to all the great news that 2012 is going to bring us.
Happy New Year!
Comments
Post a Comment